Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
IRIX's Cash-to-Debt is ranked higher than
97% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. IRIX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
IRIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.59  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.81
IRIX's Equity-to-Asset is ranked higher than
84% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. IRIX: 0.81 )
Ranked among companies with meaningful Equity-to-Asset only.
IRIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.81 Max: 0.91
Current: 0.81
0.4
0.91
Interest Coverage No Debt
IRIX's Interest Coverage is ranked higher than
96% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 93.54 vs. IRIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
IRIX' s Interest Coverage Range Over the Past 10 Years
Min: 2.06  Med: 39.7 Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 11.24
Beneish M-Score: -3.88
WACC vs ROIC
8.85%
-52.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -5.56
IRIX's Operating Margin % is ranked lower than
60% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. IRIX: -5.56 )
Ranked among companies with meaningful Operating Margin % only.
IRIX' s Operating Margin % Range Over the Past 10 Years
Min: -43.43  Med: 2.19 Max: 6.88
Current: -5.56
-43.43
6.88
Net Margin % -25.38
IRIX's Net Margin % is ranked lower than
69% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. IRIX: -25.38 )
Ranked among companies with meaningful Net Margin % only.
IRIX' s Net Margin % Range Over the Past 10 Years
Min: -40.11  Med: 5.04 Max: 23.45
Current: -25.38
-40.11
23.45
ROE % -33.26
IRIX's ROE % is ranked lower than
72% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. IRIX: -33.26 )
Ranked among companies with meaningful ROE % only.
IRIX' s ROE % Range Over the Past 10 Years
Min: -87.4  Med: 7.92 Max: 33.69
Current: -33.26
-87.4
33.69
ROA % -26.77
IRIX's ROA % is ranked lower than
70% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. IRIX: -26.77 )
Ranked among companies with meaningful ROA % only.
IRIX' s ROA % Range Over the Past 10 Years
Min: -51.3  Med: 5.92 Max: 26.59
Current: -26.77
-51.3
26.59
ROC (Joel Greenblatt) % -17.47
IRIX's ROC (Joel Greenblatt) % is ranked lower than
58% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. IRIX: -17.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IRIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -186.08  Med: 11.39 Max: 28.34
Current: -17.47
-186.08
28.34
3-Year Revenue Growth Rate 6.20
IRIX's 3-Year Revenue Growth Rate is ranked higher than
56% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. IRIX: 6.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IRIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.9  Med: 4.7 Max: 19
Current: 6.2
-21.9
19
GuruFocus has detected 2 Warning Signs with IRIDEX Corp $IRIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IRIX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

IRIX Guru Trades in Q1 2016

Jim Simons 246,300 sh (-0.04%)
» More
Q2 2016

IRIX Guru Trades in Q2 2016

Jim Simons 231,100 sh (-6.17%)
» More
Q3 2016

IRIX Guru Trades in Q3 2016

Jim Simons 210,500 sh (-8.91%)
» More
Q4 2016

IRIX Guru Trades in Q4 2016

Jim Simons 195,900 sh (-6.94%)
» More
» Details

Insider Trades

Latest Guru Trades with IRIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:PAVM, NAS:ACRX, NAS:OBLN, NAS:NVCN, NAS:FONR, NAS:CGNT, NAS:DRAD, NAS:MSON, OTCPK:IPDQF, NAS:IRMD, NAS:SPNE, NAS:RTIX, AMEX:CVRS, NAS:EDAP, OTCPK:PHMZF, NAS:EYES, NAS:NVTR, NAS:SRTS, NAS:SPAN, OTCPK:AVMXF » details
Traded in other countries:IX4.Germany,
Iridex Corp along with its subsidiaries, is a provider of therapeutic based laser console, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology.

Iridex designs, manufactures, and markets laser equipment used in the ophthalmologic and aesthetic fields. The firm concentrates its ophthalmic lasers for use in back-of-the-eye diseases such as glaucoma, age-related macular degeneration, and diabetic retinopathy. Iridex receives about 45% of its total revenue from outside the United States.

Ratios

vs
industry
vs
history
PB Ratio 3.75
IRIX's PB Ratio is ranked lower than
56% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. IRIX: 3.75 )
Ranked among companies with meaningful PB Ratio only.
IRIX' s PB Ratio Range Over the Past 10 Years
Min: 0.41  Med: 1.87 Max: 4.75
Current: 3.75
0.41
4.75
PS Ratio 2.85
IRIX's PS Ratio is ranked higher than
54% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. IRIX: 2.85 )
Ranked among companies with meaningful PS Ratio only.
IRIX' s PS Ratio Range Over the Past 10 Years
Min: 0.11  Med: 1.37 Max: 3.58
Current: 2.85
0.11
3.58
EV-to-EBIT -49.15
IRIX's EV-to-EBIT is ranked lower than
99.99% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.96 vs. IRIX: -49.15 )
Ranked among companies with meaningful EV-to-EBIT only.
IRIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.3  Med: 13.9 Max: 3566.3
Current: -49.15
-154.3
3566.3
EV-to-EBITDA -65.76
IRIX's EV-to-EBITDA is ranked lower than
99.99% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.54 vs. IRIX: -65.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
IRIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -380.1  Med: 11.1 Max: 227.1
Current: -65.76
-380.1
227.1
Current Ratio 5.42
IRIX's Current Ratio is ranked higher than
85% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. IRIX: 5.42 )
Ranked among companies with meaningful Current Ratio only.
IRIX' s Current Ratio Range Over the Past 10 Years
Min: 1.28  Med: 4.7 Max: 10.41
Current: 5.42
1.28
10.41
Quick Ratio 4.04
IRIX's Quick Ratio is ranked higher than
80% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. IRIX: 4.04 )
Ranked among companies with meaningful Quick Ratio only.
IRIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 3.46 Max: 7.8
Current: 4.04
0.7
7.8
Days Inventory 169.27
IRIX's Days Inventory is ranked lower than
68% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. IRIX: 169.27 )
Ranked among companies with meaningful Days Inventory only.
IRIX' s Days Inventory Range Over the Past 10 Years
Min: 132.97  Med: 166.97 Max: 233.91
Current: 169.27
132.97
233.91
Days Sales Outstanding 79.27
IRIX's Days Sales Outstanding is ranked lower than
64% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. IRIX: 79.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.34  Med: 65.86 Max: 84.53
Current: 79.27
58.34
84.53
Days Payable 28.75
IRIX's Days Payable is ranked lower than
80% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. IRIX: 28.75 )
Ranked among companies with meaningful Days Payable only.
IRIX' s Days Payable Range Over the Past 10 Years
Min: 28.75  Med: 34.25 Max: 43.87
Current: 28.75
28.75
43.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
IRIX's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. IRIX: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IRIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.5  Med: -3.3 Max: 1.5
Current: -4.5
-6.5
1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.92
IRIX's Price-to-Net-Cash is ranked higher than
61% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 15.26 vs. IRIX: 9.92 )
Ranked among companies with meaningful Price-to-Net-Cash only.
IRIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.64  Med: 6.47 Max: 48.89
Current: 9.92
2.64
48.89
Price-to-Net-Current-Asset-Value 3.99
IRIX's Price-to-Net-Current-Asset-Value is ranked higher than
71% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. IRIX: 3.99 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
IRIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.73  Med: 1.95 Max: 4.31
Current: 3.99
0.73
4.31
Price-to-Tangible-Book 3.82
IRIX's Price-to-Tangible-Book is ranked higher than
53% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. IRIX: 3.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IRIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.65  Med: 1.83 Max: 4.13
Current: 3.82
0.65
4.13
Price-to-Intrinsic-Value-Projected-FCF 3.88
IRIX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
73% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. IRIX: 3.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IRIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.42  Med: 1.73 Max: 4.51
Current: 3.88
0.42
4.51
Price-to-Median-PS-Value 2.09
IRIX's Price-to-Median-PS-Value is ranked lower than
90% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. IRIX: 2.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IRIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.89 Max: 2.26
Current: 2.09
0.11
2.26
Earnings Yield (Greenblatt) % -2.03
IRIX's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. IRIX: -2.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IRIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.03  Med: 3.4 Max: 13.5
Current: -2.03
-2.03
13.5

More Statistics

Revenue (TTM) (Mil) $46.16
EPS (TTM) $ -1.15
Beta0.86
Short Percentage of Float4.70%
52-Week Range $9.61 - 16.64
Shares Outstanding (Mil)11.52

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 49 60
EPS ($) -0.46 -0.11
EPS without NRI ($) -0.46 -0.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IRIX

Headlines

Articles On GuruFocus.com
IRIDEX Corp. Reports Operating Results (10-Q) Nov 04 2010 
IRIDEX Corp. Reports Operating Results (10-Q) Aug 05 2010 
IRIDEX Corp. Reports Operating Results (10-Q) May 06 2010 
IRIDEX Corp. Reports Operating Results (10-Q) Nov 12 2009 
IRIDEX Corp. Reports Operating Results (10-Q) Aug 13 2009 
IRIDEX Corp. Reports Operating Results (10-Q) May 15 2009 
IRIDEX Corp. (IRIX) CFO James H Mackaness buys 2,000 Shares Mar 13 2009 

More From Other Websites
IRIDEX CORP Financials Mar 21 2017
IRIDEX Corp. :IRIX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
New Strong Sell Stocks for March 17th Mar 17 2017
Edited Transcript of IRIX earnings conference call or presentation 8-Mar-17 10:00pm GMT Mar 17 2017
IRIDEX CORP Files SEC form 10-K, Annual Report Mar 15 2017
IRIDEX To Present At The Sidoti & Co. Spring 2017 Convention Mar 15 2017
IRIDEX CORP Files SEC form 8-K, Change in Directors or Principal Officers Mar 13 2017
Iridex reports 4Q loss Mar 08 2017
Iridex reports 4Q loss Mar 08 2017
IRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 08 2017
IRIDEX Announces Fourth Quarter and 2016 Financial Results and Provides Full Year 2017 Financial... Mar 08 2017
Q4 2016 IRIDEX Corp Earnings Release - After Market Close Mar 08 2017
IRIDEX To Present At 29th Annual Roth Conference Feb 28 2017
8:03 am IRIDEX announces the availability of the G-Probe Illuminate, a new, FDA-cleared probe... Feb 28 2017
IRIDEX Launches New FDA-Cleared Probe At The Annual American Glaucoma Society Meeting Feb 28 2017
IRIDEX to Report Fourth Quarter and 2016 Financial Results on March 8, 2017 Feb 22 2017
ETFs with exposure to IRIDEX Corp. : January 19, 2017 Jan 19 2017
IRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 10 2017
IRIDEX Announces Preliminary Unaudited Revenues for 2016 Fourth Quarter and Full Year Jan 09 2017
ETFs with exposure to IRIDEX Corp. : December 22, 2016 Dec 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)